CytRx to Present at Upcoming Virtual LD Micro Conference

Rhea-AI Summary

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical company specialized in oncology and neurodegenerative disease research, announced that Steven A. Kriegsman, its CEO, will present at the Virtual LD Micro Main Event XIV from October 12-14, 2021. The presentation will be available for on-demand viewing throughout the conference. CytRx, which joined the LD Micro Index in 2021, is focused on developing novel therapeutics, including its drug conjugate, aldoxorubicin, licensed to ImmunityBio, and arimoclomol, sold to Orphazyme for milestone payments and royalties.

LOS ANGELES--(BUSINESS WIRE)-- CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that Steven A. Kriegsman, Chairman and Chief Executive Officer of CytRx, is scheduled to present at the Virtual LD Micro Main Event XIV, which is being held from October 12-14, 2021.

Mr. Kriegsman’s virtual presentation will be available for on-demand viewing throughout the conference. Interested parties can view the presentation here.

As a reminder, CytRx joined the LD Micro Index in 2021.

About CytRx Corporation
CytRx Corporation (OTCQB: CYTR) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer and neurodegenerative diseases. CytRx’s most recent advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to ImmunityBio, Inc. In addition, CytRx’s drug candidate, arimoclomol, was sold to Orphazyme A/S in exchange for milestone payments and royalties. Orphazyme is developing arimoclomol in two indications, including Niemann-Pick disease Type C (NPC), and Gaucher disease. CytRx Corporation’s website is www.cytrx.com.

About LD Micro
LD Micro was founded in 2006 as an independent resource to the microcap world and quickly grew to the premier event platform in the space, LDmicro.com. In September of 2020, LD Micro was acquired by SRAX, who recently hosted the LD Micro event on their Sequire platform, ve.mysequire.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005597/en/

MKA

Greg Marose / Bela Kirpalani

gmarose@mkacomms.com / bkirpalani@mkacomms.com

Source: CytRx Corporation

FAQ

When is CytRx's presentation at the LD Micro Main Event XIV?

CytRx's presentation will take place during the Virtual LD Micro Main Event XIV from October 12-14, 2021.

How can I watch CytRx's presentation?

CytRx's presentation will be available for on-demand viewing throughout the conference.

What is the focus of CytRx Corporation?

CytRx Corporation focuses on research and development in oncology and neurodegenerative diseases.

What drug did CytRx Corporation license to ImmunityBio?

CytRx licensed its advanced drug conjugate, aldoxorubicin, to ImmunityBio.

What milestone payments has CytRx received related to arimoclomol?

CytRx sold its drug candidate arimoclomol to Orphazyme A/S in exchange for milestone payments and royalties.